Andrzej Jakubowiak, MD, PhD

Andrzej Jakubowiak, MD, PhD, explains promising results for KRd maintenance and the potential of modifying the posttransplant maintenance paradigm in multiple myeloma.

Andrzej Jakubowiak, MD, PhD, addressed why using multidrug regimens to remove the need for autologous transplant in multiple myeloma could benefit patients.

A trial comparing triplet maintenance to lenalidomide alone demonstrated improved progression-free and overall survival in transplant-eligible multiple myeloma.

Andrzej Jakubowiak, MD, PhD, discusses how the ATLAS trial intensified, then deescalated posttransplant maintenance in newly diagnosed multiple myeloma.

During a Targeted Oncology Case-Base Roundtable event, Andrzej Jakubowiak, MD, PhD, led a discussion on new agents for the treatment of multiple myeloma.

Andrzej Jakubowiak, MD, PhD, professor of Medicine, University of Chicago Medicine, discusses safety results from an open label, phase 1b trial  exploring daratumumab (Darzalex) combined with carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone in patients with newly diagnosed multiple myeloma.

Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, University of Chicago Medicine, discusses the toxicity profile of panobinostat in combination with bortezomib and dexamethasone in relapsed or relapsed/refractory multiple myeloma as seen in the PANORAMA trial.